Scholars Central

Conference abstractPublished 12 Nov 2018

CNS clinical trials-the challenges

Authors: Susan McGoldrick

The CNS Company, Stirling, Scotland, UK

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The failure rate for drugs in late-stage clinical trials is high; however, in CNS disorders it is spectacularly high. For example, in Alzheimerâ??s disease, 99.6% of drugs in phase III clinical trials have failed. Since the burden of CNS disease is extremely high, the demand for treatments exists and is ever growing. From all the trial failures, there are, therefore, a huge amount of lessons that can be learnt if you are willing to look honestly at what has gone wrong and consider taking a different path. This talk will look at the lessons that can be learned from poor patient selection, endpoint selection and poor trial design resulting in high screen failures and withdrawals.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Neurological Disorders.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalNeurological Disorders
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Susan McGoldrick”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels